CARY, N.C., May 19 /PRNewswire-FirstCall/ -- Cornerstone Therapeutics Inc. , formerly known as Critical Therapeutics, Inc., a specialty pharmaceutical company focused on acquiring, developing and commercializing significant products primarily for the respiratory market, today announced the departure of Scott B. Townsend, Esq., General Counsel and Executive Vice President of Legal Affairs, effective June 5, 2009. The Company has already begun a search for a successor.

"I would like to thank Scott for his contributions to the Company during his many years of service, and in particular since the closing of last year's merger," said Craig A. Collard, Cornerstone's President and Chief Executive Officer. "Scott's knowledge of Critical Therapeutics' pre-merger business was especially helpful as we integrated the operations of the combined company and filed our first post-merger Annual Report on Form 10-K and Quarterly Report on Form 10-Q, as well as the Proxy Statement for our first post-merger annual stockholders' meeting, which will be held on May 28, 2009. Scott recognized that, at this juncture in our development, we need a general counsel who is located full-time at our North Carolina headquarters, but told us that, for family reasons, he is currently unable to relocate from Massachusetts. Thus, we mutually agreed that it would be prudent to make this management change at this time. We appreciate Scott agreeing to remain with us through our annual stockholders' meeting."

Cornerstone currently retains Raleigh, North Carolina-based Smith, Anderson, Blount, Dorsett, Mitchell & Jernigan, L.L.P. as its external legal counsel.

About Cornerstone Therapeutics

Cornerstone Therapeutics Inc. , headquartered in Cary, N.C., is a specialty pharmaceutical company focused on acquiring, developing and commercializing significant products primarily for the respiratory and related markets. The Company currently promotes multiple marketed products in the United States to respiratory-focused physicians and key retail pharmacies with its specialty sales force. The Company also has a late-stage clinical pipeline with five regulatory approval submissions targeted within the next three years. Key elements of the Company's strategy are to in-license or acquire rights to underpromoted, patent-protected, branded respiratory or related pharmaceutical products, or late-stage product candidates; implement life cycle management strategies to maximize the potential value and competitive position of the Company's currently marketed products, newly acquired products and product candidates that are currently in development; grow product revenue through the Company's specialty sales force which is focused on the respiratory and related markets; and maintain and strengthen the intellectual property position of the Company's currently marketed products, newly acquired products and product candidates.

Safe Harbor Statement

Statements in this press release regarding the progress and timing of our product development programs and related trials; our future opportunities; our strategy, future operations, financial position, future revenues and projected costs; our management's prospects, plans and objectives; and any other statements about management's future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including, without limitation, statements containing the words "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "should," "target," "will," "would" and similar expressions) should also be considered to be forward-looking statements.

There are a number of important factors that could cause our actual results or events to differ materially from those indicated by such forward-looking statements, including risks relating to our ability to develop and maintain the necessary sales, marketing, supply chain, distribution and manufacturing capabilities to commercialize our products, including difficulties relating to the manufacture of ZYFLO CR(R) tablets; the possibility that the Food and Drug Administration (the FDA) will take enforcement action against us or one or more of our marketed drugs that do not have FDA-approved marketing applications; patient, physician and third-party payor acceptance of our products as safe and effective therapeutic products; our ability to maintain regulatory approvals to market and sell our products that do have FDA approved marketing applications; our ability to enter into additional strategic licensing, collaboration or co-promotion transactions on favorable terms, if at all; our ability to maintain compliance with NASDAQ listing requirements; adverse side effects experienced by patients taking our products; difficulties relating to clinical trials, including difficulties or delays in the completion of patient enrollment, data collection or data analysis; the results of preclinical studies and clinical trials with respect to our products under development and whether such results will be indicative of results obtained in later clinical trials; our ability to satisfy FDA and other regulatory requirements; our ability to obtain, maintain and enforce patent and other intellectual property protection for our products and product candidates; and the other factors described in Item 1A (Risk Factors) of our Quarterly Report on Form 10Q filed with the Securities and Exchange Commission (the SEC) on May 7, 2009 and other filings that we make with the SEC. If one or more of these factors materialize, or if any underlying assumptions prove incorrect, our actual results, performance or achievements may vary materially from any future results, performance or achievements expressed or implied by these forward-looking statements.

In addition, the statements in this press release reflect our expectations and beliefs as of the date of this release. We anticipate that subsequent events and developments will cause our expectations and beliefs to change. However, while we may elect to update these forward-looking statements publicly at some point in the future, we specifically disclaim any obligation to do so, whether as a result of new information, future events or otherwise. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, business development transactions, joint ventures or investments that we may make. These forward-looking statements should not be relied upon as representing our views as of any date after the date of this release.

ZYFLO CR(R) is a trademark of Cornerstone Therapeutics Inc.

CONTACT: Investor Relations Evan Smith, evan.smith@fd.com, or Brian
Ritchie, brian.ritchie@fd.com, or Media Relations Robert Stanislaro,
robert.stanislaro@fd.com, all of FD, +1-212-850-5600